SGPSpyGlass Pharma, Inc.
$28.41
$28.41
$17.5652 weeks$29.68
Price
End-of-day closes, not the intraday tick.
The five questions
2 of 5 availableOnly two of the five can be answered for SGP today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
P/En/a
Market value$950.3M
1 yearn/a
5 yearsn/a
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 5, 2026, a quarter after the last one.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 19, 2026On October 19, 2026, SpyGlass Pharma, Inc. issued a press release providing positive interim 4-year data from its first-in-human trial of its Bimatoprost Drug Pad-IOL System.Other event · Form 8-K
- Oct 1, 2026On October 1, 2026, the Company entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Santen Holdings US, Inc., a California corporation (“Seller”), and Santen Pharmaceutical Co., Ltd., a Japanese Company (“Parent”)Regulation FD disclosure · Form 8-K
- Aug 6, 2026SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Biotechnology
The closest names by size in the same industry